Veracyte Inc

Veracyte Inc

  • Price (USD)44.76
  • Today's Change-0.55 / -1.21%
  • Shares traded436.43k
  • 1 Year change+92.27%
  • Beta0.7085
Data delayed at least 15 minutes, as of Apr 20 2021 19:41 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

  • Revenue in USD (TTM)117.48m
  • Net income in USD-34.91m
  • Incorporated2006
  • Employees320.00
  • Location
    Veracyte Inc6000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-7606United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VCYT:NMQ since
Decipher Biosciences IncDeal completed03 Feb 202103 Feb 2021Deal completed-31.17%600.00m
Data delayed at least 15 minutes, as of Apr 20 2021 19:41 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Addus Homecare Corporation764.78m33.13m1.70bn6.03k51.643.2337.532.222.082.0847.9533.211.00--5.42126,891.504.334.895.115.9029.5827.674.333.60--20.180.27310.0017.8817.8228.3723.8925.29--
Evolent Health Inc1.02bn-337.85m1.70bn2.90k--2.69--1.66-3.95-3.9111.787.340.7129--10.04352,563.10-23.56-14.36-29.81-17.9931.4038.25-33.04-31.22---2.890.3188--20.8060.21-11.88--37.28--
Genetron Holdings Ltd - ADR65.22m-471.54m1.72bn799.00--6.59--26.43-15.71-15.711.442.940.33387.663.3981,627.16-241.33---292.04--61.30---723.00--7.70-0.09050.0681--31.25---353.98------
CorVel Corporation554.16m43.29m2.01bn3.82k47.219.5730.163.622.382.3830.4511.731.26--8.54144,916.109.8413.5214.7921.1121.4120.497.816.65----0.00---0.5903.752.6810.637.19--
MEDNAX Inc1.73bn-9.58m2.28bn5.60k--3.03120.921.32-0.1147-9.5320.738.730.4628--4.68309,634.10-0.25573.11-0.29443.44-----0.55256.72--1.890.70---2.57-9.01-122.70--1.24--
Magellan Health Inc4.58bn4.05m2.44bn9.00k512.431.3019.870.5330.183414.92180.4272.241.42100.785.58508,614.600.12541.530.16962.252.804.010.08840.8742.861.110.25120.000.261-0.0866-67.88-33.631.07--
Irhythm Technologies Inc265.17m-43.83m2.61bn1.16k--7.61--9.85-1.59-1.599.5511.770.648415.039.86229,184.10-10.72-20.56-12.52-24.4473.5073.34-16.53-25.245.67-28.750.0881--23.5948.9719.68--49.96--
Surgery Partners Inc1.86bn-155.60m2.61bn10.80k--19.0527.201.41-3.19-3.1938.1410.900.356627.135.25172,231.500.02490.63090.03520.887425.1228.200.06991.621.341.060.6377--1.5714.15-40.81--5.11--
Accolade Inc155.57m-48.07m2.69bn1.23k--6.53--17.29-1.13-1.133.487.040.5801--18.14124,453.60-17.92---24.65--43.43---30.90-----9.560.00--39.76--9.08------
Agape ATP Corp3.45m354.77k2.82bn35.008,064.52476.544,388.03817.750.00090.00090.00920.01570.5981--9.9698,646.296.15--6.81--77.53--10.28--4.91--0.00--------------
Veracyte Inc117.48m-34.91m3.04bn320.00--6.26--25.84-0.6686-0.66862.217.240.32087.236.22367,134.40-9.53-15.78-10.00-17.2164.7164.72-29.71-28.4622.11-154.540.0019---2.4018.87-177.08---14.38--
Burning Rock Biotech Ltd(ADR)66.05m-72.51m3.14bn938.00--8.46--47.55-0.7031-0.70310.64193.550.24491.844.2970,418.49-23.20---26.23--73.02---94.73--10.17--0.019--12.64---41.22------
InnovAge Holding Corp607.14m-19.72m3.23bn1.91k------5.32-0.148-0.1484.56-0.2837------317,873.80--------27.11---3.33----0.88061.12--21.81--34.22------
Option Care Health Inc3.03bn-8.08m3.48bn5.15k--3.4249.791.15-0.0485-0.048516.875.651.1617.139.29589,314.00-0.3084-2.80-0.3611-3.3422.5025.24-0.2663-
CareDx Inc192.19m-18.71m3.78bn456.00--12.98--19.65-0.4114-0.41144.145.620.73897.886.55421,478.10-7.19-16.84-8.99-23.1467.1662.03-9.74-22.753.80-18.410.0003--51.2546.8514.81--53.92--
Progyny Inc344.86m46.46m4.30bn210.00106.2525.7388.9912.480.46450.46453.601.921.71--5.621,642,181.0022.98--32.00--20.32--13.47------0.00--50.15--642.18------
Data as of Apr 20 2021. Currency figures normalised to Veracyte Inc's reporting currency: US Dollar USD

Institutional shareholders

61.02%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Dec 20209.03m13.47%
William Blair Investment Management LLCas of 31 Dec 20205.25m7.83%
BlackRock Fund Advisorsas of 31 Dec 20204.36m6.50%
The Vanguard Group, Inc.as of 31 Dec 20204.08m6.09%
Invesco Advisers, Inc.as of 31 Dec 20203.55m5.31%
Artisan Partners LPas of 31 Dec 20203.53m5.27%
Nikko Asset Management Americas, Inc.as of 31 Dec 20203.27m4.88%
Gilder, Gagnon, Howe & Co. LLCas of 31 Dec 20202.96m4.42%
Wellington Management Co. LLPas of 31 Dec 20202.68m4.01%
SSgA Funds Management, Inc.as of 31 Dec 20202.16m3.23%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.